Biogen ($BIIB) has fleshed out its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new co will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq market.
It will include commercialized hemophilia drugs Eloctate and Alprolix, which are partnered with Swedish Orphan Biovitrum (Sobi), as well as a pipeline including gene therapy programs for hemophilia A and B, a non-factor bispecific antibody program to treat patients with hemophilia A and those with inhibitors, as well as sickle cell disease research.
“We've chosen to spin off our growing hemophilia business, because we believe it's the right decision to ensure fit and focus,” said outgoing Biogen CEO George Scangos on the company’s July earnings call.
Bioverativ will be headed by CEO John Cox, formerly Biogen EVP of Pharmaceutical Operations & Technology. “The new company’s name creates a clear connection to our Biogen heritage and biotech focus,” he said in a statement. Biogen first announced its spinoff plans earlier this year in May.
The new company is expected to use the revenues from the marketed drugs to support continued R&D in blood disorders. Specifically, it hopes to create longer acting therapies based on its XTEN technology and get this into the clinic during the first half of 2017. In addition, it expects to move faster on the development for bispecific antibodies and hemophilia-related gene therapy programs.
Bioverativ also plans to conduct clinical testing on Eloctate as a potential means to rapidly induce immune tolerance in hemophilia patients who develop inhibitors.
- here is the announcement
Related Articles:
Biogen inks a $100M hemophilia deal with a Polaris-backed startup
BioMarin up on positive gene therapy data in hemophilia A
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Biotechs jockey for gene therapy lead with hemophilia data ‘snapshots’
Biogen CEO George Scangos to step down